Brief: E.F. Hutton Advises On Strategic Merger Between Apimeds And Mindwave
17/12/2025 13:27
Dec 17 (Reuters) - Apimeds Pharmaceuticals US Inc APUS.A: E.F. HUTTON ADVISES ON STRATEGIC MERGER BETWEEN APIMEDS AND MINDWAVE, ALIGNING BIOTECH GROWTH WITH AI-ENABLED FINANCIAL INNOVATION Source text: ID:nGNX7dNQJc Further company coverage: APUS.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apimeds Pharmaceuticals US
See all newsBrief: Mindwave Innovations Signs 3 Client Network Agreements In 10 Days, Extending Mindchain Into Climate Finance, Sports Media And Insurance Apimeds Pharmaceuticals Us Provides Required NYSE American Disclosure
Brief: Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19
Brief: Apimeds Pharmaceuticals Us Inc Vin Menon Continues To Serve As The Company’S Chief Executive Officer
Brief: Apimeds Pharmaceuticals Appoints Youngjik Cho As Chairman Of Board
Brief: Apimeds Pharmaceuticals Us Inc. Announces Material Breach Of Merger Agreement By Inscobee Inc And Apimeds Inc